Abstract
INTRODUCTION
Alzheimer’s Disease Neuroimaging Initiative (ADNI) has been pivotal in identifying and refining Alzheimer’s disease (AD) biomarkers for clinical trials. This study leverages longitudinal data from participants who have progressed to amyloid-positivity during their study participation to track evolution of biomarkers and cognitive function.
METHODS
We modeled AD biomarker (positron emission tomography [PET], structural, cerebrospinal fluid [CSF], cognition) trajectories before and after observed amyloid-positivity onset time to detect time at which each biomarker had detectable trajectory changes.
RESULTS
Analysis of a sub-cohort of the 20-year ADNI study (N = 90) recapitulated Alzheimer’s progression beginning with amyloid alterations -4.8 to -5.3 years relative to amyloid-positivity, succeeded by neurodegeneration (t = -4.0 to -4.1 years), and CSF tau (t = -0.4 to -0.5 years). Cognitive decline was observed to significantly correspond with emergence of amyloid-positivity (t = 0.2 to 2.4 years).
DISCUSSION
Our results corroborate temporal progression curves of AD biomarkers, providing insights on earliest detectable changes in objective and subjective cognitive function assessments.
If you do not see content above, kindly GO TO SOURCE.
Not all publishers encode content in a way that enables republishing at Neuro.vip.
This post is Copyright: Tamar Schaap,
Pamela Thropp,
Duygu Tosun,
for the Alzheimer’s Disease Neuroimaging Initiative | October 21, 2024